PEANUT trial: assessing salvage therapy for metastatic urothelial carcinoma

Written by Lucy Chard, Editor

nab-paclitaxel tumor therapy

Presented at the first AACR Virtual Annual Meeting, the PEANUT trial is an open-label, single-arm Phase II clinical trial looking into the use of Pembrolizumab and nanoparticle albumin bound paclitaxel (nab-paclitaxel) as a possible salvage therapy for metastatic urothelial carcinoma. The trial studied 64 patients, with inclusion criteria including histological confirmation of urothelial carcinoma of the bladder or urothelium and demonstrated failure of a standard platinum-based chemotherapy treatment. The study, led by Patrizia Giannatempo and a team of researchers from Fondazione IRCCS Istituto Nazionale Tumori (Milan, Italy), San Raffaele Hospital and Scientific Institute (Milan, Italy) and Foundation Medicine (MA, USA)...

To view this content, please register now for access

It's completely free